Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles:in vitroandin vivostudies

Abstract

The development of magnetic nanoparticles as delivery carriers to magnetically accumulate anticancer drug in cancer tissue has attracted immense interest. In the present study, magnetic mesoporous silica nanoparticles (MMSNs) with magnetite core and silica shell were synthesized. The obtained MMSNs were characterized by DLS, XRD, FT-IR, TEM and VSM in order to investigate the nanoparticle characteristics. With the focus on in vivo validation of such magnetic drug delivery systems, we selected epirubicin (EPI) as the drug. The anticancer properties of EPI-loaded MMSNs were evaluated in a C-26 colon carcinoma model. Alongside monitoring of drug in the tissues with animal imaging system, the tissue distribution was also determined quantitavely. The average size of MMSNs determined with TEM images was about 18.68 ± 2.31 nm. The cellular uptake test indicated that geometric mean fluorescence intensity (MFI) of cells treated with MMSN + EPI in presence of external magnetic field was increasing 27% compared with free EPI. In addition, treatment with drug-loaded MMSNs with the aid of external magnetic gradient had significantly higher inhibition efficacy towards tumor growth than the free EPI treated mice. The targeted drug delivery through external magnet-attraction using EPI-loaded MMSNs resulted in high tumor cell uptake, which leads to elimination of cancer cells effectively.

Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach

“…In total, there were 376 data sets from 200 NP tumor delivery studies in tumor-bearing mice that were included for PBPK simulations and analyses (Table S1). − ,,,− ,− ,,,,,− …”

Hybrid System for Local Drug Delivery and Magnetic Hyperthermia Based on SPIONs Loaded with Doxorubicin and Epirubicin

“…Application of SPIONs as drug carriers delivering conjugated chemotherapeutics seems to be an interesting strategy, especially for decreasing the side effects when the SPION-based conjugate is injected locally. Recently, well-known cytostatics from anthracyclines like doxorubicin (Dox) and its analog epirubicin (Epi), well-known for their effectiveness in cancer therapy, bring attention to application in magnetic nanocarriers [ 42 , 43 , 44 , 45 , 46 ]. Using SPIONs modified with anthracyclines puts together cancer triggering by the drug and the magnetic hyperthermia for a more efficient triggering of cancer cells.…”

Enhanced theranostic efficacy of epirubicin-loaded SPION@MSN through co-delivery of an anti-miR-21-expressing plasmid and ZIF-8 hybridization to target colon adenocarcinoma

“…In comparison, previous studies utilizing MSN nanoparticles achieved EE% and LC% of approximately 47% and 16% for EPI, respectively. 61,62 The second therapeutic agent, a DNA plasmid, was loaded onto the nanocarriers with an experimental loading efficiency determined by the ratio of the nanocarrier/plasmid (C/P = 10). Similar to previous studies, the optimal C/P ratio was determined through agarose gel electrophoresis.…”